Drugs Archives - Page 19 of 66

KHN’s ‘What the Health?’: Wrapping Up Summer’s Health News

President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.

Aug. 18, 2022

A woman with wearing a black T-shirt and orange skirt is filling her car up with gas at the station. The car, to the right of the image, is black and glossy. She faces the gas pump and recoils at the price.

For Medically Vulnerable Families, Inflation’s Squeeze Is Inescapable

Inflation hasn’t hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.

By Heidi de Marco

Aug. 15, 2022

A photo shows the exterior of the U.S. Capitol building.

Big Pharma Went All In to Kill Drug Pricing Negotiations

For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.

By Arthur Allen

Aug. 12, 2022

KHN & PolitiFact HealthCheck

No, the Senate-Passed Reconciliation Bill Won’t Strip $300 Billion From Medicare

Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.

By Louis Jacobson, PolitiFact

Aug. 11, 2022

KHN & PolitiFact HealthCheck

A GOP Talking Point Suggests Birth Control Is Not at Risk. Evidence Suggests Otherwise.

Republicans say Democrats are wrong to claim that birth control could be the Supreme Court’s next target. But Democrats have plenty of evidence that it might be.

By Julie Rovner

Aug. 5, 2022

A screenshot shows Julie Rovner sitting in the PBS Newshour studio.

KHN On Air

Watch: Explaining the Nitty-Gritty of Medicare Drug Price Negotiations — And Patients’ Potential Savings

KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats’ plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.

Aug. 1, 2022

A photo shows a gloved hand holding a box of paxlovid. A blister pack of tablets is seen on the table.

COVID-19

Everything You Need to Know About Paxlovid — Especially, Should You Take It?

Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.

By Michelle Andrews

July 28, 2022

KHN On Air

Listen: Can California Lower the Price of Insulin?

California Healthline senior correspondent Angela Hart describes California’s ambitious plan to manufacture generic insulin under the state’s new “CalRx” drug label.

July 27, 2022

KHN & PolitiFact HealthCheck

Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations

The advocacy group American Commitment said empowering Medicare to negotiate drug prices would raid it of billions of dollars. Drug pricing experts say that that’s not the case and that such policies would instead reduce costs for the Medicare program and seniors.

By Victoria Knight and Colleen DeGuzman

July 25, 2022

Podcast

KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate

Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.

July 21, 2022

A family photo shows Jacob Boggs holding his daughter Emma and standing next to his daughter Riley and his wife Courtney Boggs.

Parents Become Drug Developers to Save Their Children’s Lives

Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.

By Jared Whitlock

July 21, 2022

A photo shows a blister pack of pills against a blue background.

As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger

Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.

By Arthur Allen

July 15, 2022

Letters to the Editor

A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness

KHN gives readers a chance to comment on a recent batch of stories.

July 15, 2022

Podcast

KHN’s ‘What the Health?’: Life After ‘Roe’ Is … Confusing

A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

July 14, 2022

A tincture bottle of CBD oil is seen on a table. A warning on the label reads, "Shake before use."

Patients With Epilepsy Navigate Murky Unregulated CBD Industry

The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.

By Eric Berger

July 13, 2022

Seeking to Kick-Start Biden’s Agenda, Schumer Unveils a Bill for Medicare Drug Price Negotiations

In addition to allowing federal officials to negotiate the price that Medicare pays for some drugs, the bill would cap annual out-of-pocket drug costs for Medicare beneficiaries at $2,000. But before Democrats can pass the bill under special rules that prevent Republicans from staging a filibuster, they must get approval from the Senate parliamentarian.

By Michael McAuliff

July 7, 2022

A photo shows a patient's blood pressure being checked with an arm cuff.

‘Free’ Screening? Know Your Rights to Get No-Cost Care

Even a decade in, the Affordable Care Act’s recommendations to simply cover preventive screening and care without cost sharing remain confusing and complex.

By Julie Appleby

July 6, 2022

How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence

The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.

By Arthur Allen

July 5, 2022

Letters to the Editor

Readers and Tweeters Weigh In on Medical Debt, the Obesity Epidemic, and Opioid Battles

KHN gives readers a chance to comment on a recent batch of stories.

June 24, 2022

Podcast

KHN’s ‘What the Health?’: The FDA Goes After Nicotine

The FDA is using its power to regulate tobacco products — ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.

June 23, 2022

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics

Drugs